Skip to content

Effect of esketamine on brain injury during Cardiopulmonary Bypass in Cardiac surgery

Effect of esketamine on brain injury during Cardiopulmonary Bypass in Cardiac surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069914
Enrollment
Unknown
Registered
2023-03-29
Start date
2023-04-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain injury

Interventions

esketamine group:To apply esketamine before cardiopulmonary bypass
placebo group:To apply equal volume of normal saline during anesthesia induction and maintenance

Sponsors

Jinan Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients undergoing thoracotomy cardiac surgery due to severe valve stenosis, insufficiency, atrial septal or ventricular septal defect, and aortic dissection. (2) The preoperative coagulation test was normal (partial thromboplastin time 24-39s and international normalized ratio of thromboplastin 0.8-1.2, platelets 100-300*10^9). (3) Patients who have not received strong thrombolysis, anticoagulation and antiplatelet therapy in the past week. (4) Preoperative left ventricular ejection fraction >= 30%.

Exclusion criteria

Exclusion criteria: (1) Patients with disturbance of consciousness, stroke, or mental illness before surgery. (2) Patients who have been using psychotropic and anesthetic drugs for a long time (such as opioids, non-steroidal antipyretic, analgesic and anti-inflammatory drugs, sedatives, antidepressants), alcohol abuse patients, and patients with a history of abnormal surgery and anesthesia recovery. (3) Chronic wasting diseases such as blood diseases, severe immune disorders, and cancer. (4) Severe heart, lung, liver and kidney insufficiency. (5) Those who have been enrolled in other clinical drug experiments within three months or are allergic to the research drugs.

Design outcomes

Primary

MeasureTime frame
Serum neuro-specific enolase;Serum S100b protein;

Secondary

MeasureTime frame
C-reactive protein;Interleukin-6;Cerebral oxygen saturation;Blood gas analysis;cardiac troponin I, cTnI;brain natriuretic peptide, BNP;Ramsay sedation score;Mini-mental State Examination,MMSE;SAS/SDS Self Assessment Scale;

Countries

China

Contacts

Public ContactJun Xu

Jinan Central Hospital

junxu_584521@126.com+86 133 2510 8917

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026